(Q38104293)

28 August 2017

The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives (English)

1 reference

28 August 2017

Xi-Mei Wang

1

1 reference

28 August 2017

Yue-Jin Yang

series ordinal

2

1 reference

28 August 2017

Yong-Jian Wu

series ordinal

3

1 reference

28 August 2017

1 August 2013

1 reference

Cardiovascular Drugs and Therapy

28 August 2017

1 reference

28 August 2017

27

1 reference

28 August 2017

4

1 reference

28 August 2017

297-307

1 reference

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

28 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase IV inhibitors and diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6459-8

10.1007/S10557-013-6459-8

21 January 2018

Identifiers

DOI

1 reference

release_ltgt2jykujg4tauzoxnv4vgguq

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ltgt2jykujg4tauzoxnv4vgguq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference